L. Dick

发表

An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer

Amanda Doucette, Mansoureh Rezaei, Alice McDonald, 2009, Nature.

Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids.

L. Dick, R. Stein, M. Behnke, 1998, Bioorganic & medicinal chemistry letters.

Ubiquitin-like protein conjugation and the ubiquitin–proteasome system as drug targets

James Lowe, Lynn Bedford, J. Lowe, 2010, Nature Reviews Drug Discovery.

MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-{kappa}B-dependent lymphoma.

Mark Manfredi, Lenny Dang, Usha Narayanan, 2010, Blood.

Degradation of oxidized insulin B chain by the multiproteinase complex macropain (proteasome).

G N DeMartino, C. Slaughter, L. Dick, 1991, Biochemistry.

Metabolism of vasoactive peptides by plasma and purified renal aminopeptidase M.

L. Dick, I. Benter, S. Wilk, 1990, Biochemical pharmacology.

Kinetic studies of the branched chain amino acid preferring peptidase activity of the 20S proteasome: development of a continuous assay and inhibition by tripeptide aldehydes and clasto-lactacystin beta-lactone.

L. Dick, R. Stein, L. Grenier, 1998, Biochemistry.

Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids.

L. Dick, R. Stein, M. Behnke, 1998, Bioorganic & medicinal chemistry letters.

The structure of the PA28–20S proteasome complex from Plasmodium falciparum and implications for proteostasis

L. Tilley, M. Parker, C. Morton, 2019, Nature Microbiology.

4924 , a NEDD 8-activating enzyme inhibitor , is active in diffuse large B-cell lymphoma models : rationale for treatment of NF-B – dependent lymphoma *

L. Staudt, U. Narayanan, L. Dang, 2010 .

Artemisinin kills malaria parasites by damaging proteins and inhibiting the proteasome

S. Ralph, L. Tilley, L. Dick, 2018, Nature Communications.

The proteasome as a target for protozoan parasites

L. Tilley, L. Dick, A. Gould, 2019, Expert opinion on therapeutic targets.

Characterization of the Loss of SUMO Pathway Function on Cancer Cells and Tumor Proliferation

Xingyue He, J. Newcomb, J. Brownell, 2015, PloS one.

Mechanistic Studies on the Inactivation of the Proteasome by Lactacystin in Cultured Cells*

L. Dick, V. Palombella, R. Stein, 1997, The Journal of Biological Chemistry.

Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer.

M. Rolfe, A. Berger, Jie Yu, 2010, Cancer research.

Distinct Specificities of Mycobacterium tuberculosis and Mammalian Proteasomes for N-Acetyl Tripeptide Substrates*

L. Dick, C. Nathan, C. Tsu, 2008, Journal of Biological Chemistry.

Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy.

L. Dick, P. Fleming, 2010, Drug discovery today.

Changes in the ratio of free NEDD8 to ubiquitin triggers NEDDylation by ubiquitin enzymes

L. Dick, Roland Hjerpe, Y. Thomas, 2011, The Biochemical journal.

Quantifiable analysis of cellular pathway inhibition of a Nedd8-activating enzyme inhibitor, MLN4924, using AlphaScreen.

L. Dick, K. Garcia, A. Burkhardt, 2013, Analytical biochemistry.

Characterization of a New Series of Non-covalent Proteasome Inhibitors with Exquisite Potency and Selectivity for the 20s Β5-subunit Figure S1 Activities of Compound 1 and Bortezomib in Cells

T. Soucy, E. Olhava, M. Sintchak, 2010 .

Second-Generation Proteasome Inhibitors

D. Esseltine, K. Anderson, L. Dick, 2011 .

Proteasome inhibitors bortezomib and carfilzomib used for the treatment of multiple myeloma do not inhibit the serine protease HtrA2/Omi† †Electronic supplementary information (ESI) available. See DOI: 10.1039/c6tx00220j

L. Dick, F. Wolenski, V. Csizmadia, 2016, Toxicology research.

Cleavage Specificity of Mycobacterium tuberculosis ClpP1P2 Protease and Identification of Novel Peptide Substrates and Boronate Inhibitors with Anti-bacterial Activity*

Christopher Tsu, A. Goldberg, T. Akopian, 2015, The Journal of Biological Chemistry.

Proteasome inhibitors bortezomib and car fi lzomib used for the treatment of multiple myeloma do not inhibit the serine protease HtrA 2 / Omi †

L. Dick, F. Wolenski, V. Csizmadia, 2016 .

A new model of cancer cachexia: contribution of the ubiquitin-proteasome pathway.

A. Goldberg, P. Elliott, L. Dick, 1999, American journal of physiology. Endocrinology and metabolism.

A new model of cancer cachexia: contribution of the ubiquitin-proteasome pathway.

A. Goldberg, P. Elliott, L. Dick, 1999, The American journal of physiology.

Comparison of biochemical and biological effects of ML858 (salinosporamide A) and bortezomib

M. Rolfe, G. Weatherhead, Julie Zhang, 2006, Molecular Cancer Therapeutics.

Active Site-directed Inhibitors of Rhodococcus 20 S Proteasome

W. Baumeister, L. Dick, C. Slaughter, 1997, The Journal of Biological Chemistry.

13C NMR of methylated lysines of fd gene 5 protein: evidence for a conformational change involving lysine 24 upon binding of a negatively charged lanthanide chelate.

L. Dick, A. Sherry, C. Geraldes, 1989, Biochemistry.

Distinct Specificities of Mycobacterium tuberculosis and Mammalian Proteasomes for N-Acetyl Tripeptide Substrates*

L. Dick, C. Nathan, C. Tsu, 2008, Journal of Biological Chemistry.

Reaction hijacking of tyrosine tRNA synthetase as a whole-of-life-cycle antimalarial strategy

E. Winzeler, M. Parker, C. Morton, 2022, Science.

The NEDD8 Conjugation Pathway and Its Relevance in Cancer Biology and Therapy.

Peter G. Smith, T. Soucy, M. Milhollen, 2010, Genes & cancer.

4924 , a NEDD 8-activating enzyme inhibitor , is active in diffuse large B-cell lymphoma models : rationale for treatment of NF-B – dependent lymphoma *

L. Staudt, U. Narayanan, L. Dang, 2010 .

Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules

A. Goldberg, K. Rock, L. Dick, 1994, Cell.

Identification and localization of a cysteinyl residue critical for the trypsin-like catalytic activity of the proteasome.

C. Slaughter, L. Dick, G. Demartino, 1992, Biochemistry.

Substrate-assisted inhibition of ubiquitin-like protein-activating enzymes: the NEDD8 E1 inhibitor MLN4924 forms a NEDD8-AMP mimetic in situ.

Ping Li, Hua Liao, M. Rolfe, 2010, Molecular cell.

Mechanistic Studies of Substrate-assisted Inhibition of Ubiquitin-activating Enzyme by Adenosine Sulfamate Analogues

M. Milhollen, James M. Gavin, J. Brownell, 2011, The Journal of Biological Chemistry.

Optimization of a series of dipeptides with a P3 β-neopentyl asparagine residue as non-covalent inhibitors of the chymotrypsin-like activity of human 20S proteasome

M. Sintchak, L. Dick, J. Blank, 2012 .

Optimization of a series of dipeptides with a P3 threonine residue as non-covalent inhibitors of the chymotrypsin-like activity of the human 20S proteasome.

Jonathan L Blank, Christopher Tsu, Christopher Blackburn, 2010, Bioorganic & medicinal chemistry letters.

Autoubiquitination of the 26S Proteasome on Rpn13 Regulates Breakdown of Ubiquitin Conjugates

S. Gygi, A. Goldberg, N. Kukushkin, 2014, The EMBO journal.

Development of a charcoal paper adenosine triphosphate:pyrophosphate exchange assay: kinetic characterization of NEDD8 activating enzyme.

L. Dick, O. Tayber, C. Tsu, 2009, Analytical biochemistry.

Novel Small-Molecule Inhibitors of RNA Polymerase III

L. Dick, T. Ocain, Vala Thoroddsen, 2003, Eukaryotic Cell.

A small-molecule inhibitor of the ubiquitin activating enzyme for cancer treatment

S. Tirrell, J. Newcomb, T. Soucy, 2018, Nature Medicine.

Probing the roles of SUMOylation in cancer cell biology by using a selective SAE inhibitor.

Pooja Shah, Hua Liao, John Newcomb, 2017, Nature chemical biology.

Hydrolysis of Biological Peptides by Human Angiotensin-converting Enzyme-related Carboxypeptidase*

T. Parsons, James M. Gavin, L. Dick, 2002, The Journal of Biological Chemistry.

Treatment-emergent mutations in NAEβ confer resistance to the NEDD8-activating enzyme inhibitor MLN4924.

Usha Narayanan, U. Narayanan, Peter G. Smith, 2012, Cancer cell.

Proteolytic Processing of Ovalbumin and β-galactosidase by the Proteasome to Yield Antigenic Peptides

Clive A. Slaughter, George N. DeMartino, Stephen C. Jameson, 1994 .

Kinetic characterization of the chymotryptic activity of the 20S proteasome.

L. Dick, R. Stein, F. Melandri, 1996, Biochemistry.

Artemisinin kills malaria parasites by damaging proteins and inhibiting the proteasome

S. Ralph, L. Tilley, L. Dick, 2018, Nature Communications.

Proteolytic processing of ovalbumin and beta-galactosidase by the proteasome to a yield antigenic peptides.

C. Slaughter, M. Bevan, S. Jameson, 1994, Journal of immunology.

Mechanistic Studies on the Inactivation of the Proteasome by Lactacystin

L. Dick, R. Stein, L. Grenier, 1996, The Journal of Biological Chemistry.

Rate of Ubiquitination and Proteasomal Degradation of Topoisomerase I Determines Cellular Resistance to Cancer Drug

L. Dick, A. Berger, S. Pulukuri, 2021 .

Absolute Quantification of E1, Ubiquitin-Like Proteins and Nedd8–MLN4924 Adduct by Mass Spectrometry

T. Soucy, J. Brownell, Michael P. Thomas, 2013, Cell Biochemistry and Biophysics.

Characterization of a new series of non-covalent proteasome inhibitors with exquisite potency and selectivity for the 20S β5-subunit

T. Soucy, E. Olhava, M. Sintchak, 2010, The Biochemical journal.

Mycobacterium tuberculosis prcBA genes encode a gated proteasome with broad oligopeptide specificity

T. Parsons, Huilin Li, P. Zwickl, 2006, Molecular microbiology.

Structure of the Mycobacterium tuberculosis proteasome and mechanism of inhibition by a peptidyl boronate

Huilin Li, L. Dick, C. Nathan, 2006, Molecular microbiology.

Target Validation and Identification of Novel Boronate Inhibitors of the Plasmodium falciparum Proteasome

E. Winzeler, L. Tilley, L. Dick, 2018, Journal of medicinal chemistry.

Design of proteasome inhibitors with oral efficacy in vivo against Plasmodium falciparum and selectivity over the human proteasome

E. Winzeler, L. Tilley, D. Fidock, 2021, Proceedings of the National Academy of Sciences.

Use of structure-based drug design approaches to obtain novel anthranilic acid acyl carrier protein synthase inhibitors.

Dominick Quagliato, Diane Joseph-McCarthy, Elena Severina, 2005, Journal of medicinal chemistry.

Mechanistic Studies on Activation of Ubiquitin and Di-ubiquitin-like Protein, FAT10, by Ubiquitin-like Modifier Activating Enzyme 6, Uba6*

James M. Gavin, J. Brownell, L. Dick, 2012, The Journal of Biological Chemistry.

Preclinical evaluation of the antitumor activity of bortezomib in combination with vitamin C or with epigallocatechin gallate, a component of green tea

A. Berger, Jie Yu, L. Dick, 2011, Cancer Chemotherapy and Pharmacology.

Interaction of Reductively Methylated Lysyl-Fd Gene 5 Protein with a Negatively Charged Lanthanide Paramagnetic Macrocyclic Chelate or with Oligonucleotides using 13-C NMR

L. Dick, A. Sherry, C. Geraldes, 1991 .

Identification of Potent and Selective Non-covalent Inhibitors of the Plasmodium falciparum Proteasome

M. Bogyo, L. Dick, C. Blackburn, 2014, Journal of the American Chemical Society.

Mechanistic Study of Uba5 Enzyme and the Ufm1 Conjugation Pathway

James M. Gavin, M. Sintchak, L. Dick, 2014, The Journal of Biological Chemistry.

Reductive methylation and 13C NMR studies of the lysyl residues of fd gene 5 protein. Lysines 24, 46, and 69 may be involved in nucleic acid binding.

L. Dick, A. Sherry, D. Gray, 1988, The Journal of biological chemistry.

N,C-Capped dipeptides with selectivity for mycobacterial proteasome over human proteasomes: role of S3 and S1 binding pockets.

M. Sintchak, L. Dick, C. Nathan, 2013, Journal of the American Chemical Society.

Absolute Quantification of E1, Ubiquitin-Like Proteins and Nedd8–MLN4924 Adduct by Mass Spectrometry

J. Brownell, Michael P. Thomas, L. Dick, 2013, Cell Biochemistry and Biophysics.